Blood Clot News and Research

RSS

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

10 Feb 2011

Luciferase enzyme offers promise for improved monitoring of heparin therapy: New study

The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.

10 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Pharmacist-directed anticoagulation service improves quality of care for HIT patients

A Henry Ford Hospital study has found that a pharmacist-directed anticoagulation service improves the way medication is managed for patients with heparin-induced thrombocytopenia, a common but life-threatening thromboembolic disorder.

9 Feb 2011

FDA approves Makena injection to reduce risk of preterm delivery

The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one spontaneous preterm birth.

5 Feb 2011

Scientists discover how stressed cells boost thrombin production

In our not-so-distant evolutionary past, stress often meant imminent danger, and the risk of blood loss, so part of our body's stress response is to stock-pile blood-clotting factors. Scientists in the Molecular Medicine Partnership Unit, a collaboration between the European Molecular Biology Laboratory in Heidelberg, Germany, and the University of Heidelberg Medical Centre, have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin.

4 Feb 2011

Scientists discover how stressed cells boost production of key blood-clotting factor, thrombin

Scientists in a collaboration between EMBL Heidelberg and the University of Heidelberg Medical Centre have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin. Their work, published today in Molecular Cell, shows how cancer cells may be taking advantage of this process, and opens new possibilities for fighting back against cancer and septicaemia.

4 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Researchers design nanoparticles that make blood clots visible to CT scanner

For almost two decades, cardiologists have searched for ways to see dangerous blood clots before they cause heart attacks. Now, researchers at Washington University School of Medicine in St. Louis report that they have designed nanoparticles that find clots and make them visible to a new kind of X-ray technology.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

Vegetarians, vegans need to increase omega-3 fatty acids and vitamin B12 to reduce heart disease risk

People who follow a vegan lifestyle - strict vegetarians who try to eat no meat or animal products of any kind - may increase their risk of developing blood clots and atherosclerosis or "hardening of the arteries," which are conditions that can lead to heart attacks and stroke. That's the conclusion of a review of dozens of articles published on the biochemistry of vegetarianism during the past 30 years.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Patients unaware of stroke risk with irregular heart beat conditions

Thousand of people who suffer from irregular heartbeats or conditions termed as arrhythmias are unaware they are at high risk of suffering a stroke. A new survey found that two of three people do not know the warning signs of shortness of breath and palpitations. Experts estimate that more than 4,000 strokes a year could be prevented by better awareness among the general public and doctors of the heart condition atrial fibrillation (AF) this manifests as palpitations and irregular heart beat.

31 Jan 2011

How estrogen decreases risk and delays onset and progression of Alzheimer's disease

An influential article in the journal Progress in Neurobiology provided one of the first comprehensive reviews of how estrogen potentially can protect against Alzheimer's disease and other neurological disorders.

27 Jan 2011

Microvisk secures £6 million to launch world's first diagnostic SmartStrip

Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, has raised £6 million through a rights issue to existing investors in an oversubscribed round. This is the third successful funding round for Microvisk, which has secured £10.5m in the past 12 months - the largest amount raised by a UK life science company**.

26 Jan 2011

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.

23 Jan 2011

Blood Clot News and Research

Further Reading

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Luciferase enzyme offers promise for improved monitoring of heparin therapy: New study

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Pharmacist-directed anticoagulation service improves quality of care for HIT patients

FDA approves Makena injection to reduce risk of preterm delivery

Scientists discover how stressed cells boost thrombin production

Scientists discover how stressed cells boost production of key blood-clotting factor, thrombin

CVT more common than previously thought, disproportionally affects pregnant women

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

Researchers design nanoparticles that make blood clots visible to CT scanner

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Vegetarians, vegans need to increase omega-3 fatty acids and vitamin B12 to reduce heart disease risk

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Scientist identifies natural signaling molecule that can prevent Hemophilia A

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Patients unaware of stroke risk with irregular heart beat conditions

How estrogen decreases risk and delays onset and progression of Alzheimer's disease

Microvisk secures £6 million to launch world's first diagnostic SmartStrip

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News